Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir

Scand J Infect Dis. 2010 Mar;42(3):237-9. doi: 10.3109/00365540903447018.

Abstract

In patients with virological failure during highly active antiretroviral therapy (HAART) and drug resistance, guidelines recommend the achievement of maximal virological suppression by the use of a new regimen with at least 2 active drugs. We describe the clinical outcome of a heavily antiretroviral-experienced patient who experienced early failure to raltegravir.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Salvage Therapy / methods*
  • Treatment Failure

Substances

  • Anti-HIV Agents
  • Pyrrolidinones
  • Raltegravir Potassium